Professional Documents
Culture Documents
There is an algorithm in swartz for the management of small bowel obstruction as Figure 28-16 at page 1232, but for this
learning objectives, it was instructed to make our own management for adhesive small bowel obstruction. So for our
algorithm as shown, If there are signs and symptoms of strangulation ( fever, tachycardia or tachynea, localized abdominal
tenderness, leukocytosis) and intestinal ischemia (blood flow to your intestines decreases) then proceed to the operation
room for exploration. If no then, it will be characterized if partial bowel obstruction or complete bowel obstruction. For partial
bowel obstruction. The patient will proceed to NPO, IVF, NGT, Serial abdominal exam. And if the patient develops signs or
symptoms of intestinal ischemia, then proceed to operation room for exploration, and if they are no signs or symptoms of
intestinal ischemia, continue conservative management duration dependent on etiology and surgeon choice. For complete
bowel obstruction, the patient will have NPO, IVF, NGT, and serial abdominal exam, and if the patient develops signs or
symptoms of intestinal ischemia then proceed to operating room for exploration. And if no symptoms of intestinal ischemia,
improving after 24 hours of conservative management, then continue management, and no improvement proceed to
operating room for exploration.
So for case 2,
A 40-year-old male was admitted in the hospital 20 days post-op after developing a partial small bowel obstruction
secondary to multiple abdominal incisional hernias that required repair; recovery was complicated by the
development of multiple intraabdominal abscesses. His history was significant for a motor vehicle crash dating back
to 2002 where he sustained multiple orthopedic and intra-abdominal injuries that required numerous surgical
interventions. Before transfer to our facility, he underwent lysis of adhesions, repair of multiple hernias and
resection of a loop of small bowel (ileum) with a primary anastomosis after a bowel perforation.
Currently he presented in the ER with a deep wound infection at the inferior pole of the laparotomy site. He has
stable vital signs but show signs of dehydration. Bilious succus fluid was noted to drain from the wound. Daily
wound drainage was estimated to range from 250-330 cc for the past 4 days.
According to swartzs, A fistula is defined as an abnormal communication between two epithelialized surfaces. The
communication occurs between two parts of the gastrointestinal tract or adjacent organs in an internal fistula or Gi tract with
the skin (An external fistula).
Moreover, Internal fistula- occurs between two parts of the gastrointestinal tract or adjacent organs. And examples of internal
fistulas are enterocolonic fistula or colovesicular fistula. An external fistula involves the skin or another external surface
epithelium. And enterocutaneous fistula or rectovaginal fistula for its examples.
((limits dietary fibre to less than 10-15g per day and restricts other foods that
could stimulate bowel activity. The goal of a LRD is to decrease the size and
frequency of bowel movements in order to reduce painful symptoms.))
▪ Moderate output fistula- those that drains between 200 and 500 mL per day
o And high-output fistulas those that drain more than 500 mL of fluid per day. High-output fistulas are
treated surgically unless you can convert it to a low-output fistula. To decrease output give octreotide
or somastostatin.
((MOA Somatostatin and Octreotide- The proposed mechanisms of action include a reduction in splanchnic and
gastroduodenal mucosal blood flow, a decrease in GI motility, inhibition of gastric acid secretion, inhibition of
pepsin secretion, and gastric mucosal cytoprotective effects.)
((A subcutaneous injection is a method of administering medication. Subcutaneous means under the skin. In
this type of injection, a short needle is used to inject a drug into the tissue layer between the skin and the
muscle.))
So for our case, the patient has an estimation of 250-330 cc or mL daily wound drainage for the past 4 days he has
a moderate output fistula.
A fistula is an abnormal communication between two epithelialized surfaces; an
enterocutaneous fistula (ECF), as the name indicates, is an abnormal communication
between the small or large bowel and the skin. An ECF can arise from the duodenum,
jejunum, ileum, colon, or rectum. (See the image below.)
Laboratory Studies
The following laboratory studies are performed in the evaluation of an enterocutaneous
fistula (ECF):
• Total white blood cell (WBC) count - This is important because sepsis can lead to
leukocytosis
• Serum sodium, potassium, and chloride levels - Electrolyte abnormalities can
result from fluid and electrolyte loss
• Complete blood count (CBC), total proteins, serum albumin, and globulin - These
can demonstrate the presence of malnutrition-associated
anemia/hypoalbuminemia
• Serum transferrin - Low levels (< 200 mg/dL) are a predictor of poor healing
• Serum C-reactive protein (CRP) - Levels may be elevated
Imaging Studies
Fistulography
During fistulography (see the images below), a water-soluble contrast agent is injected into
the fistulous tract.
Methylene blue diluted in saline can be administered through a nasogastric tube as a simple
bedside test to confirm the presence of an ECF, especially in patients with a
gastrocutaneous or lateral duodenal fistula. This test can also help to determine whether the
leak is from a segment that is in the continuity of the gastrointestinal tract, especially in the
case of proximal fistulas. However, because methylene blue loses diagnostic efficacy as it
becomes diluted with intestinal secretions, its role in identifying distal ECFs is limited.
Approach Considerations
The conventional therapy for an enterocutaneous fistula (ECF) in the initial phase is always
conservative. Immediate surgical therapy on presentation is contraindicated, because the
majority of ECFs spontaneously close as a result of conservative therapy. Surgical
intervention in the presence of sepsis and poor general condition would be hazardous for the
patient.
However, patients who have an ECF with adverse factors, such as a lateral duodenal fistula,
an ileal fistula, a high-output fistula, or a fistula associated with a diseased bowel, may
require early surgical intervention.
Zhou et al described a novel technique of using the orchid Bletilla striata in the closure of
ECF. [20] In a case of ECF following colonic neoplasm resection managed conservatively,
application of B striata led to spontaneous closure of the fistula. This plant was found to
suppress inflammation and promote wound healing.
Conservative Therapy
Conservative treatment should usually be administered for a period ranging from a few
weeks to a few months. The principles of nonsurgical therapy for ECFs include the following:
• Rehydration
• Administration of antibiotics
• Correction of anemia
• Electrolyte repletion
• Drainage of obvious abscess
• Nutritional support
• Control of fistula drainage
• Skin protection
With the above-mentioned supportive therapy, spontaneous closure occurs in almost 70% of
patients. In a study of 186 patients, Reber et al found that 91% of small-bowel fistulas that
closed spontaneously did so within 1 month after sepsis was cured. The remaining fistulas
that closed spontaneously did so by the end of 3 months after sepsis cure, with the rest of
the lesions requiring surgical closure. [21]
Uba et al reported that the majority of ECFs in children closed spontaneously following high-
protein and high-carbohydrate nutrition. [22] They found that hypoalbuminemia and jejunal
location were important variables resulting in nonspontaneous closure, whereas
hypokalemia, sepsis, and hypoproteinemia/hypoalbuminemia were risk factors for high
mortality in children with ECF.
Rehydration, electrolyte repletion, and nutritional support
Common fluid and electrolyte problems that must be corrected in patients with an ECF
include the following:
• Dehydration
• Hyponatremia
• Hypokalemia
• Metabolic acidosis
The author uses parenteral nutrition more often in patients with a proximal small-bowel ECF,
especially if it is in the proximal jejunum, or with a high-output fistula. In patients with a distal
ECF, the author prefers to use enteral nutrition whenever possible.
Studies have shown that the provision of only 20% of calories fed enterally may protect the
integrity of the mucosal barrier, as well as the immunologic and hormonal function of the
gut. [12] Hence, a combination of parenteral and enteral nutrition can be used. In high-output
fistulas, the author uses this combination therapy.
In patients with a proximal fistula, if a nasojejunal tube can be introduced beyond the site of
the fistula, then these patients can be supported with enteral nutrition, provided that there is
at least 4-5 ft (1.2-1.5 m) of small bowel distal to it and no distal obstruction. Patients with
chronic small-bowel ECFs may need additional supplementation with copper, folic acid, and
vitamin B12. [12]
Total parenteral nutrition
Total parenteral nutrition (TPN) is usually indicated with suspected gastric, duodenal, or
small-bowel fistula. When the fistula output is very high, discontinuance of oral intake is
recommended because oral intake stimulates further losses of fluids, electrolytes, and
protein via the fistula. A decrease in fistula output frequently occurs with the initiation of TPN.
Home parenteral nutrition (HPN) is a vital therapy for patients who have the diagnosis of
ECF, and it has reported to be successful for patients with ECF as compared with other HPN
patients. [23] Greater provision of protein, more frequent NPO (nil per os) status, and a goal of
future surgery should be the focus in ECF patients on HPN.
Water requirements for TPN are 1 mL/kcal/day. Electrolyte requirements for TPN are as
follows:
• Sodium (Na) - 80-100 mEq/day
• Potassium (K) - 75-100 mEq/day
• Magnesium (Mg) - 15-20 mEq/day
• Calcium (Ca) - 15-20 mEq/day
Calorie and protein requirements are as follows:
• Maintenance – 25-30 kcal, 1.0-1.2 g/kg/day
• Moderate stress – 30-40 kcal, 1.3-1.4 g/kg/day
• Severe stress – 40-45 kcal, 1.5-2.0 g/kg/day
Protein (g)/6.25 should equal nitrogen (g), and the nonprotein calorie-to-nitrogen ratio should
be as follows:
• Maintenance - 200-300:1
• Moderate stress - 150:1
• Severe stress - < 100:1
A standard, general-purpose formula for TPN consists of the following:
• Glucose, 75 g
• Amino acids, 20 g
• Lipids, 30 g/L
The introduction of ethyl vinyl acetate bags has made the admixture of fat emulsion with
dextrose and amino acids possible (three-in-one concept). [24] This leads to a more uniform
administration of a balanced solution containing the three macronutrients plus micronutrients
over a 24-hour period.
Enteral nutrition
Enteral nutrition is the mainstay of treatment for patients with ECFs. In fistulas of the distal
ileum, colon, or duodenum, enteral nutrition should be considered and can be administered
via various routes. Conventionally, when a gastroduodenal anastomosis or closure is needed
in adverse conditions, a concomitant feeding jejunostomy is performed, so that access is
available for enteral nutritional support in case of an anastomotic leak.
The other routes of administration can be via nasogastric/jejunal tubes or a gastrostomy.
High rates of feeding should be avoided to prevent hyperosmolar diarrhea. Elemental diets,
that is, nonresidue balanced diets with protein components reduced to their basic elements,
are preferred. When a tube enterostomy is performed, proper fixation is necessary to prevent
complications, such as dislodgment of the tube or antegrade migration in the gastrointestinal
(GI) tract. [25]
Martinez et al reported a prospective randomized trial on the effect of preoperative
administration of oral arginine and glutamine in 40 patients with ECF undergoing definitive
surgery, of whom 20 received standard medical care (control group) and 20 received enteral
supplementation with arginine 4.5 g/day and glutamine 10 g/day for 7 days prior to surgery
(test group). [26] The primary outcome was recurrence; secondary outcomes were pre- and
postoperative serum interleukin (IL)-6 and C-reactive protein (CRP) levels and infectious
complications. The recurrence rate was 10% in the test group and 45% in the control group.
The test group had lower IL-6 and CRP levels and no infectious complications.
Fistuloclysis
Enteral nutrition can also be administered in patients with high-output proximal
jejunocutaneous or ileocutaneous fistulas with good mucocutaneous continuity. Feeding can
be administered through a feeding tube inserted in the distal limb of the ECF. Teubner et al
and Ham et al reported good results with this method in select patients to improve the
nutrition of the patient, which is helpful for subsequent fistula closure and promotes healing
of the fistula. [27, 28, 29] An interprofessional approach is needed. [30]
Skin management
Irrgang et al developed a fistula assessment guide that has aided skin management related
to ECFs. [31] This guide is based on the following characteristics:
• Origin of fistula
• Nature of effluent
• Condition of skin
• Location of fistula opening
For a high-output fistula, a pouch system is preferable to a conventional skin dressing. For a
low-output fistula, a skin barrier with a dressing or pouch is advocated.
The degree of skin irritation present (from erythema to maceration to skin loss) guides the
type of skin-protecting agents that should be applied and the type of pouch system that
should be used. In addition, an important consideration is whether the opening is flush with
the skin, retracted and deep, close to bony prominences, or in an open wound.
Pouches used for skin care
When the fistula output is high, it is desirable to use a pouch for collecting the enteric
effluents. Ostomy pouches in one- or two-piece designs with either a drainable clip or a
urostomy-type closure can be cut and fit to perifistular skin. If the area of the fistula is on an
irregular body contour (eg, close to bony prominences), then a one-piece pouch is more
suitable because it can adhere better.
A transparent pouch is preferred to an opaque pouch, for visualization of the fistula. A pouch
with a skin-barrier backing is more durable than one with an adhesive backing. Wound
manager bags (see the image below) are preferable in that they are specifically designed to
help make wound care easier with good skin protection and access to the wound for its care.
Wound manager.
View Media Gallery
Skin barriers
Powder, paste, wafers, spray, and creams are used as skin barriers for the protection of skin
from the enteric effluents.
Pectin-based wafers that melt and seal with the skin provide a good barrier and offer
protection for a variable period before the skin breaks down and ulcerates. In low-output
fistulas, absorbent dressings can be put on top of the skin-barrier wafer to absorb any
effluent overflow. The skin wafer protects the adjoining skin from erythema and maceration.
Pectin- or karaya-based powders and paste are used. Powders are preferred over a paste in
wet, weepy, perifistular skin when severe skin maceration is present. A generous amount of
powder should be used and continuously added for good results. In patients with weepy skin
and a high-output fistula, management becomes difficult.
A spray provides a protective film and is helpful for pouching, but it might not be beneficial if
used alone.
Zinc creams (see the images below) are used to waterproof and protect the skin. Again, a
generous amount with continuous replacement is necessary because the cream is washed
away with discharging enteric effluents.